JP2017511329A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511329A5
JP2017511329A5 JP2016560389A JP2016560389A JP2017511329A5 JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5 JP 2016560389 A JP2016560389 A JP 2016560389A JP 2016560389 A JP2016560389 A JP 2016560389A JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5
Authority
JP
Japan
Prior art keywords
oxy
amine
dimethylpentan
methyl
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511329A (ja
JP6411541B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023805 external-priority patent/WO2015153720A1/en
Publication of JP2017511329A publication Critical patent/JP2017511329A/ja
Publication of JP2017511329A5 publication Critical patent/JP2017511329A5/ja
Application granted granted Critical
Publication of JP6411541B2 publication Critical patent/JP6411541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560389A 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤 Active JP6411541B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973942P 2014-04-02 2014-04-02
US61/973,942 2014-04-02
US201462061591P 2014-10-08 2014-10-08
US62/061,591 2014-10-08
PCT/US2015/023805 WO2015153720A1 (en) 2014-04-02 2015-04-01 Biaryl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017511329A JP2017511329A (ja) 2017-04-20
JP2017511329A5 true JP2017511329A5 (Direct) 2018-03-15
JP6411541B2 JP6411541B2 (ja) 2018-10-24

Family

ID=52988448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560389A Active JP6411541B2 (ja) 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤

Country Status (27)

Country Link
US (7) US9902722B2 (Direct)
EP (1) EP3126351B1 (Direct)
JP (1) JP6411541B2 (Direct)
KR (1) KR102379518B1 (Direct)
CN (1) CN106458994B (Direct)
AU (1) AU2015240869B2 (Direct)
BR (1) BR112016022298B1 (Direct)
CA (1) CA2944466C (Direct)
CL (1) CL2016002502A1 (Direct)
CY (1) CY1120988T1 (Direct)
DK (1) DK3126351T3 (Direct)
EA (1) EA028942B1 (Direct)
ES (1) ES2700549T3 (Direct)
HR (1) HRP20181899T1 (Direct)
HU (1) HUE041457T2 (Direct)
IL (1) IL248086B (Direct)
LT (1) LT3126351T (Direct)
MX (1) MX2016012829A (Direct)
PE (1) PE20170004A1 (Direct)
PL (1) PL3126351T3 (Direct)
PT (1) PT3126351T (Direct)
RS (1) RS58062B1 (Direct)
SG (1) SG11201608195QA (Direct)
SI (1) SI3126351T1 (Direct)
SM (1) SMT201800665T1 (Direct)
WO (1) WO2015153720A1 (Direct)
ZA (1) ZA201606767B (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523963A (ja) 2013-07-08 2016-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アリールアミドキナーゼ阻害剤
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
HUE041457T2 (hu) * 2014-04-02 2019-05-28 Bristol Myers Squibb Co Biaril kináz inhibitorok
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
ES2740224T3 (es) * 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
KR102704295B1 (ko) * 2015-10-01 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
JP6864674B2 (ja) * 2015-10-01 2021-04-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ビアリールキナーゼ阻害剤
EP3575298B1 (en) 2017-01-24 2022-03-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—2,2'—聯嘧啶基化合物、其類似物及其使用方法
AU2021259419A1 (en) 2020-04-21 2022-11-10 Lexicon Pharmaceuticals, Inc. AAK1 inhibitors for use in treating viral infections
CA3175973A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
US20230348390A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing methyl(s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenylpropionate and salt thereof
CN115667219B (zh) * 2020-05-28 2024-11-15 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
KR20240035814A (ko) * 2021-07-15 2024-03-18 시젱 하이스코 파마수티칼 씨오., 엘티디. Aak1 억제제 및 이의 용도
WO2023051749A1 (zh) * 2021-09-30 2023-04-06 武汉人福创新药物研发中心有限公司 Aak1抑制剂及其用途
WO2023167806A1 (en) 2022-03-01 2023-09-07 Lexicon Pharmaceuticals, Inc. Methods and compounds useful in the sythesis of an aak1 inhibitor
JP2025507623A (ja) 2022-03-01 2025-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド (s)-1-((2’,6-ビス(ジフルオロメチル)-[2,4’-ビピリジン]-5-イル)オキシ)-2,4-ジメチルペンタン-2-アミン及びその塩の固体形態
EP4496788A1 (en) 2022-03-23 2025-01-29 Teva Pharmaceuticals International GmbH Solid state forms of lx9211 and salts thereof
TW202423433A (zh) * 2022-11-10 2024-06-16 大陸商西藏海思科製藥有限公司 含aak1抑制劑的藥物组合物
CN120344529A (zh) * 2022-12-13 2025-07-18 上海海雁医药科技有限公司 杂环取代的五并六元杂芳基衍生物、其药物组合物及应用与制备方法
WO2024153067A1 (zh) * 2023-01-16 2024-07-25 上海海雁医药科技有限公司 杂环取代的含氮杂环衍生物、其药物组合物及应用与制备方法
WO2024207945A1 (zh) * 2023-04-07 2024-10-10 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
CN118772152B (zh) * 2023-04-07 2026-01-02 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
WO2025092928A1 (zh) * 2023-11-02 2025-05-08 西藏海思科制药有限公司 一种可抑制连接蛋白相关激酶1的化合物、制备及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
EP1720855A4 (en) * 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
WO2007120593A1 (en) * 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
JP2010518014A (ja) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な2−アミノピリジン誘導体
DK2822555T3 (en) * 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
JP2016523963A (ja) 2013-07-08 2016-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アリールアミドキナーゼ阻害剤
MX2016002924A (es) 2013-09-11 2016-06-06 Squibb Bristol Myers Co Inhibidores de cinasa a base de eter arilico.
MX2016009355A (es) 2014-01-29 2016-10-13 Bristol Myers Squibb Co Inhibidores de aril lactama cinasa.
US9932320B2 (en) 2014-01-31 2018-04-03 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
HUE041457T2 (hu) 2014-04-02 2019-05-28 Bristol Myers Squibb Co Biaril kináz inhibitorok
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
JP6864674B2 (ja) 2015-10-01 2021-04-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ビアリールキナーゼ阻害剤
KR102704295B1 (ko) * 2015-10-01 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
WO2020010295A1 (en) 2018-07-06 2020-01-09 Liqui-Box Corporation Dispensing probe for dispensing flowable material

Similar Documents

Publication Publication Date Title
JP2017511329A5 (Direct)
JP2018537408A5 (Direct)
NZ609955A (en) Sgc stimulators
ES2675760T3 (es) Compuestos terapéuticamente activos y métodos de uso de los mismos
JP5367707B2 (ja) Dhodh阻害剤としてのアザビフェニルアミノ安息香酸誘導体
JP2016523977A5 (Direct)
JP2016525076A5 (Direct)
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
JP2016525075A5 (Direct)
US10376510B2 (en) 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
JP2020502111A5 (Direct)
JP2015172062A5 (Direct)
JP2017530962A5 (Direct)
JP2011503230A5 (Direct)
RU2014124953A (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
JP2016522232A5 (Direct)
JP2012525395A5 (Direct)
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
JP2017523214A5 (Direct)
JP2013500997A5 (Direct)
RU2016102313A (ru) Биарильные производные в качестве агонистов gpr120
JP2017504652A5 (Direct)